1 Abnormal Intestinal Microbiome in Medical Disorders and Potential Reversibility by Fecal Microbiota Transplantation.

2 The tcdA negative and tcdB positive Clostridium difficile ST81 clone exhibits high-level fluoroquinolone resistance: a multi-center study in Beijing, China.

3 antimicrobial resistance and reduced susceptibility in clostridium difficile: potential consequences for induction, treatment, and recurrence of c. difficile infection

4 characterization of the adherence of clostridium difficile spores: the integrity of the outermost layer affects adherence properties of spores of the epidemic strain r20291 to components of the intestinal mucosa.

5 clostridium difficile infection outbreak in a male rehabilitation ward, hong kong (china), 2011

6 the tip of the four n-terminal α-helices of clostridium sordellii lethal toxin contains the interaction site with membrane phosphatidylserine facilitating small gtpases glucosylation

7 application of antibody-mediated therapy for treatment and prevention of clostridium difficile infection

8 convergent loss of abc transporter genes from clostridioides difficile genomes is associated with impaired tyrosine uptake and p-cresol production

9 identification of an essential region for translocation of clostridium difficile toxin b

10 prevalence of clostridium difficile infection among the patients attending a tertiary care teaching hospital

11 toxin-specific antibodies for the treatment of clostridium difficile: current status and future perspectives

12 emergence of community-acquired clostridium difficile infection: the experience of a french hospital and review of the literature

13 Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile

14 Pomegranate extract specifically inhibits Clostridium difficile growth and toxin production without disturbing the beneficial bacteria in vitro

15 Nationwide surveillance of ribotypes and antimicrobial susceptibilities of toxigenic Clostridium difficile isolates with an emphasis on reduced doxycycline and tigecycline susceptibilities among ribotype 078 lineage isolates in Taiwan

16 Molecular epidemiology of Clostridium difficile in two tertiary care hospitals in Shandong Province, China

17 Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis

18 Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value

19 National antimicrobial stewardship and fluoroquinolone-resistant Clostridium difficile in China

20 An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes

21 Diagnosing Clostridium difficile-associated diarrhea using enzyme immunoassay: the clinical significance of toxin negativity in glutamate dehydrogenase-positive patients

22 Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm

23 Community-acquired Clostridium difficile infection: an increasing public health threat

24 Emerging therapies for Clostridium difficile infection – focus on fidaxomicin

25 Bezlotoxumab for the prevention of Clostridium difficile infection: a review of current evidence and safety profile

26 Pomegranate extract specifically inhibits Clostridium difficile growth and toxin production without disturbing the beneficial bacteria in vitro

27 Nationwide surveillance of ribotypes and antimicrobial susceptibilities of toxigenic Clostridium difficile isolates with an emphasis on reduced doxycycline and tigecycline susceptibilities among ribotype 078 lineage isolates in Taiwan

28 Molecular epidemiology of Clostridium difficile in two tertiary care hospitals in Shandong Province, China

29 Statin use and the risk of Clostridium difficile infection: a systematic review with meta-analysis

30 Treatment of pediatric Clostridium difficile infection: a review on treatment efficacy and economic value

31 National antimicrobial stewardship and fluoroquinolone-resistant Clostridium difficile in China

32 An exploratory study to evaluate Clostridium difficile polymerase chain reaction ribotypes and infection outcomes

33 Diagnosing Clostridium difficile-associated diarrhea using enzyme immunoassay: the clinical significance of toxin negativity in glutamate dehydrogenase-positive patients

34 Antibiotic therapy and Clostridium difficile infection – primum non nocere – first do no harm

35 Community-acquired Clostridium difficile infection: an increasing public health threat

36 Emerging therapies for Clostridium difficile infection – focus on fidaxomicin

37 A Novel Quantitative Sampling Technique for Detection and Monitoring of Clostridium difficile Contamination in the Clinical Environment.

38 Integrated genomic epidemiology and phenotypic profiling of Clostridium difficile across intra-hospital and community populations in Colombia

39 Implementation of a Checklist to Reduce False-Positive Testing in Hospital-Acquired Clostridium Difficile Infection.

40 Clostridium difficile: Is it a new food-borne pathogen?

41 Disruption of the Gut Microbiome: Clostridium difficile Infection and the Threat of Antibiotic Resistance

42 Systematic Review of Intestinal Microbiota Transplantation (Fecal Bacteriotherapy) for Recurrent Clostridium difficile Infection

43 Bacterial Diarrhea in HIV-Infected Patients: Why Clostridium difficile, and Why Now?

44 Clostridium difficile infection in fever patients with gynecological malignancies

45 Staggered and Tapered Antibiotic Withdrawal With Administration of Kefir for Recurrent Clostridium difficile Infection

46 Antimicrobial Resistance Gene Acquisition and Depletion Following Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection

47 Differences of the Fecal Microflora With Clostridium difficile Therapies

48 Clostridium difficile Infection in Long-term Care Facilities: A Call to Action for Antimicrobial Stewardship

49 Fidaxomicin Versus Vancomycin for Clostridium difficile Infection: Meta-analysis of Pivotal Randomized Controlled Trials

50 Risk factors for Clostridium difficile-associated diarrhoea in HIV-infected patients

51 Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections

52 Epidemiology of community-acquired Clostridium difficile-associated diarrhea

53 A Decade of Experience in Primary Prevention of Clostridium difficile Infection at a Community Hospital Using the Probiotic Combination Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+)

54 Fecal Microbiota Transplant for Relapsing Clostridium difficile Infection Using a Frozen Inoculum From Unrelated Donors: A Randomized, Open-Label, Controlled Pilot Study

55 Early Fecal Microbiota Transplantation Improves Survival in Severe Clostridium difficile Infections

56 Prevalence and pathogenicity of Clostridium difficile in hospitalized patients. A French multicenter study

57 Evolving Insights Into the Epidemiology and Control of Clostridium difficile in Hospitals

58 Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial

59 Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection

60 A Randomized, Placebo-controlled Trial of Fidaxomicin for Prophylaxis of Clostridium difficile–associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation

61 Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection

62 Patient Attitudes Toward the Use of Fecal Microbiota Transplantation in the Treatment of Recurrent Clostridium difficile Infection

63 Prevalence and Pathogenicity of Clostridium difficile in Hospitalized Patients: A French Multicenter Study

64 Renal Failure and Leukocytosis Are Predictors of a Complicated Course of Clostridium difficile Infection if Measured on Day of Diagnosis

65 Pathway to Prevention of Nosocomial Clostridium difficile Infection

66 Frozen vs Fresh Fecal Microbiota Transplantation and Clinical Resolution of Diarrhea in Patients With Recurrent Clostridium difficile Infection: A Randomized Clinical Trial

67 Duodenal infusion of donor feces for recurrent Clostridium difficile

68 Risk factors for Clostridium difficile toxin-associated diarrhea

69 John G. Bartlett: Contributions to the Discovery of Clostridium difficile Antibiotic-Associated Diarrhea

70 Prevention of Clostridium difficile Infection With Probiotics

71 Lactobacillus acidophilus CL1285, Lactobacillus casei LBC80R, and Lactobacillus rhamnosus CLR2 (Bio-K+): Characterization, Manufacture, Mechanisms of Action, and Quality Control of a Specific Probiotic Combination for Primary Prevention of Clostridium difficile Infection

72 Treatment of First Recurrence of Clostridium difficile Infection: Fidaxomicin Versus Vancomycin

73 Epidemiology and outcome of Clostridium difficile infection and diarrhea in HIV infected inpatients

74 Diarrhea and Clostridium difficile Infection in Latin American Patients with AIDS

75 Dynamic changes in short- and long-term bacterial composition following fecal microbiota transplantation for recurrent Clostridium difficile infection

76 Fecal Microbial Transplants Reduce Antibiotic-resistant Genes in Patients With Recurrent Clostridium difficile Infection

77 Clostridium difficile-associated diarrhea in HIV-infected patients: epidemiology and risk factors

78 Epidemiology of Community-Acquired Clostridium difficile-Associated Diarrhea

79 The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida

80 Leaping Forward in the Treatment of Clostridium Difficile Infection: Update in 2015

81 pseudomembranous colitis: not always caused by clostridium difficile

82 antimicrobial use, human gut microbiota and clostridium difficile colonization and infection

83 severe clostridium difficile infections. a systematic literature -review-

84 translocation of clostridium difficile toxin b across polarized caco-2 cell monolayers is enhanced by toxin a

85 applying fecal microbiota transplantation (fmt) to treat recurrent clostridium difficile infections (rcdi) in children

86 pesquisa utiliza microrganismo clostridium difficile para prevenir infecções em hamsters

87 biofilm structures in a mono-associated mouse model of clostridium difficile infection

88 high mobility group box1 protein is involved in endoplasmic reticulum stress induced by clostridium difficile toxin a

89 diarrea asociada con infección por clostridium difficile, ¿es tiempo de preocuparnos en méxico?

90 epidemiological features of clostridium difficile colonizing the intestine of jordanian infants

91 yersinia infection with clostridium difficile colitis

92 epidemiological characteristics of nosocomial diarrhea caused by clostridium difficile in a tertiary level hospital in serbia

93 treating clostridium difficile infections: should fecal microbiota transplantation be reclassified from investigational drug to human tissue?

94 anaerobically cultivated human intestinal microbiota as first-line treatment for clostridium difficile infection

95 blastocystis sp. infection mimicking clostridium difficile colitis

96 refractory clostridium difficile infection successfully treated with tigecycline, rifaximin, and vancomycin

97 reducing the risk of severe complications among patients with clostridium difficile infection

98 difference in f-actin depolymerization induced by toxin b from the clostridium difficile strain vpi 10463 and toxin b from the variant clostridium difficile serotype f strain 1470

99 clostridium difficile infection and proton pump inhibitor use in hospitalized pediatric cystic fibrosis patients

100 two patients with fulminant clostridium difficile enteritis who had not undergone total colectomy: a case series and review of the literature

101 low risk of irritable bowel syndrome after clostridium difficile infection

Keyword Connections

Journals

Research Groups

Bibliographies